Dyslipidemias, Inflammation, Oxidative Stress
Conditions
Brief summary
The purpose of this study is to determine the effect of different dietary zinc intakes on fatty acid metabolism and other zinc biomarkers
Detailed description
This research is a dietary intervention study designed to evaluate the effect of progressive changes in Zn intake on fatty acid metabolism and to correlate those changes with biomarkers of dyslipidemia and insulin resistance. The main objective is to validate plasma fatty acid metabolism as a biomarker of inadequate Zn intake in subjects consuming identical diets with specific Zn content. The relative sensitivity of some fatty acid enzyme activities will also be compared to the DNA strand breaks. In addition to the primary objectives, correlations in enzyme activity with changes in fat metabolism, namely circulating triglyceride and cholesterol, will be determined. This will enable the determination of the effect of a low Zn intake on various aspects of dyslipidemia. Similar correlational analyses will be performed with clinical measures of inflammation and insulin resistance.
Interventions
OTHERDiet Zinc
4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
Sponsors
UCSF Benioff Children's Hospital Oakland
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* willing to limit food and beverage intake to that provided by the study * willing to discontinue consumption of alcoholic beverages during the study * willing to stop zinc supplementation 4 weeks prior to start of the study * has an operative understanding of English * no plans to move from the area during the study period
Exclusion criteria
* Chronic or acute metabolic disease * smoker or user of nicotine products * history of alcohol abuse, or use of illicit drugs. * Is underweight or overweight, body mass index (BMI) \< 18 or \> 30 kg/m2.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lipidomics changes | Day 0, day 15, day 57 and day 71 | Change in Fatty acid metabolism |
| DNA strand breaks changes | Day 0, day 15, day 57 and day 71 | change in COMET assay olive-tail moments |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Polar Metabolomics changes | Day 0, day 15, day 57 and day 71 | Change in Polar Metabolomics |
| Mineral analysis changes | Day 0, day 15, day 57 and day 71 | Changes in Plasma Zinc |
| Body weight changes | Day 0, day 15, day 57 and day 71 | changes in Body weight |
| Fat allocation changes | Day 0, day 15, day 57 and day 71 | Changes in waist circumference |
Countries
United States
Outcome results
None listed